TFTC Holdings Inc

Global Knowledge is one of the largest, privately held providers of training, enterprise learning services and software solutions for information technology and management professionals. The company offers a broad array of hands-on IT, project management and professional skills training featuring proprietary core and custom curriculum as well as content from leading companies, including Cisco, Microsoft, Nortel, Oracle and Red Hat. Delivered in classrooms from private facilities or over the Internet, Global Knowledge has helped Fortune 500 companies, organizations and government agencies leverage learning to turn knowledge into productivity for employees, customers and channel partners. Global Knowledge provides end-to-end learning services and solutions that create a quantifiable path to improved performance and increased knowledge for enterprise customers throughout the world. Its global learning platform for the management, delivery and tracking of learning solutions supports enterprise initiatives. Founded in 1995, Global Knowledge employs more than 800 people throughout the world and is headquartered in Cary, N.C.

Prometheus platform is a suite of integrated solutions that natively extend and enhance the functionality of your EAM, ERP, or CMMS with instant, live updates to your data on mobile or desktop. The platform creates a scalable environment that integrates all your EAM software into one cohesive experience. Prometheus platform's six modules are Routine Maintenance, Mobility, Permitting and Isolations, Reporting and Analytics, Turnaround and Outage Management, and Master Data Governance.

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that treat cancer, cardiovascular and autoimmune diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling. In structure-based drug design, scientists use detailed knowledge of the active sites of protein targets associated with particular diseases to design synthetic compounds that fight the disease. Structure-based drug design aims to create a molecule that will bind to the active site of a targeted enzyme, thereby preventing the normal chemical reaction and ultimately halting the progression of the disease. BioCryst was founded in 1986. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.